Literature DB >> 11313219

Perioral myoclonia with absence seizures: a rare epileptic syndrome.

B Bilgiç1, B Baykan, C Gürses, A Gökyiğit.   

Abstract

We present the clinical and video-EEG data on an epileptic boy whose absence seizures with marked perioral movements had started at the age of 1.5 years. From age 12 years, he experienced frequent episodes of typical absence status epilepticus (ASE) lasting 1-2 hours with marked perioral myoclonia and moderate confusion. Initial therapy with carbamazepine was substituted by valproate because of worsening of the absence seizures. At the age of 17, the patient was admitted to our clinic with his usual, but long lasting ASE attack, accompanied by 2 generalized tonic-clonic convulsions. ASE was confirmed with the EEG which showed continuous 3 Hz spike and wave paroxysms with occasional normal intervals of 1-5 seconds. IV injection of clonazepam improved the clinical and EEG findings immediately. Video- EEG examination performed after a few weeks demonstrated typical absence seizures with perioral myoclonia. Based on the characteristics of seizure semiology, other clinical data and EEG findings, the patient was diagnosed as having the syndrome of "perioral myoclonia with absence seizures" described by Panayiotopoulos.

Entities:  

Mesh:

Year:  2001        PMID: 11313219

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  2 in total

1.  Isolated nostril myoclonus: A novel ictal presentation in structural generalised epilepsy.

Authors:  Oliver R Marmoy
Journal:  Clin Neurophysiol Pract       Date:  2019-03-14

2.  Generalized Fast Discharges Along the Genetic Generalized Epilepsy Spectrum: Clinical and Prognostic Significance.

Authors:  Emanuele Cerulli Irelli; Francesca Antonietta Barone; Luisa Mari; Alessandra Morano; Biagio Orlando; Enrico Michele Salamone; Angela Marchi; Martina Fanella; Jinane Fattouch; Fabio Placidi; Anna Teresa Giallonardo; Francesca Izzi; Carlo Di Bonaventura
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.